Evaluation of CCL18 serum levels and genetic variant as prognostic biomarkers in SSc-ILD Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases Year: 2021
Serum biomarkers in SSc-ILD: association with presence, severity and prognosis Source: International Congress 2019 – From biomarkers to treatment of immune-mediated interstitial lung disease: what’s new? Year: 2019
The functional polymorphisms in the IL-18 gene promoter is associated with the pathogenesis of sarcoidosis Source: Eur Respir J 2003; 22: Suppl. 45, 180s Year: 2003
Correlation of cytokine gene polymorphisms and BALF cytokine levels in ILD Source: Annual Congress 2008 - Role of bronchoalveolar lavage in studying the pathophysiology of interstitial lung disease Year: 2008
Procalcitonin and C-reactive protein levels correlate worse with organ failure than NT-proBNP levels in septic patients Source: Eur Respir J 2006; 28: Suppl. 50, 61s Year: 2006
Different cutoff values of serum SP-D for German and Japanese to diagnose idiopathic interstitial pneumonias are related to different SFTPD gene polymorphisms Source: Annual Congress 2012 - Cystic lung diseases: lung granulomatosis Year: 2012
Serum KL-6 as a biomarker to assess risk of worse outcome in patients with SARS-CoV2 infection Source: Virtual Congress 2021 – COVID - 19 biomarkers Year: 2021
Serum CC16 is a potential predictor for IPF diagnosis and prognosis Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis Year: 2020
Serum microRNA signatures identified in a genome-wide profiling predict the mortality of patients with sepsis Source: Annual Congress 2011 - New aspects in prevention and treatment of community-acquired pneumonia and lower respiratory tract infections Year: 2011
Elevated serum inflammatory markers in patients with stable COPD Source: Annual Congress 2009 - Respiratory mechanics, tissue and cell dysfunction in pulmonary disease Year: 2009
Increased CCL18 serum levels in patients with pulmonary fibrosis which reflect disease severity Source: Eur Respir J 2005; 26: Suppl. 49, 21s Year: 2005
Circulating total leptin as a diagnostic and prognostic biomarker in sepsis Source: International Congress 2019 – ECMO, ECCO2R and other rescue therapies in acute respiratory failure Year: 2019
Circulating fetuin-A as a biomarker predicting mortality in ICU septic patients Source: International Congress 2017 – Sepsis, infections, ARDS and beyond Year: 2017
Individual variation in the levels of procalcitonin, neopterin, CRP and MR-proANP during a COPD exacerbation and clinical stable state Source: Annual Congress 2009 - Exacerbations of COPD and bronchiectasis: aetiology and treatment Year: 2009
High level of serum SP-D with normal range of KL-6 predicts a good prognosis of patients with fibrotic changes on HRCT Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease Year: 2010
Prognostic role of CCL18 serum concentrations in patients with idiopathic pulmonary fibrosis Source: Eur Respir J 2007; 30: Suppl. 51, 574s Year: 2007
Characterisation of asthma subgroups associated with circulating YKL-40 levels Source: Eur Respir J, 50 (4) 1700800; 10.1183/13993003.00800-2017 Year: 2017
The polymorphisms of C-reactive protein gene modify the association between central obesity, asthma and lung function in Taiwan Source: Annual Congress 2011 - Respiratory epidemiology: genetics and modifiable risk factors Year: 2011
Usefulness of serum procalcitonin in lung cancer patients with elevated serum C-reactive protein level Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer Year: 2011
TNF-alpha and TNF-beta gene polymorphism in Polish patients with sarcoidosis. Connection with the susceptibility and prognosisSource: Annual Congress 2008 - Sarcoidosis: pathophysiology and severity Year: 2008